Why the FDA Said No to First In Class Dapagliflozin
More Diabetes In Control Jul 30, 2011, 7:58 pm
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9 to 6 against recommending the approval of the first in class novel antidiabetic agent dapagliflozin, largely because of fears that the product may cause breast and bladder cancer….
… Read the Rest
- Keywords: diabetes, diabetes newsletter, diabetic newsletter, diabetes, news for diabetics, news for doctors, diabetes in children, diabetes in control,
health, blood sugars, diabetes type 1, diabetes type 2, health care, blood sugars, low blood sugars, lower blood sugars, a1cnow, hba1c, hemoglobin a1c, sportbrain,
tacticon, diabetes care, pharmacy
- Description: Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better
help their diabetes patients.